718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

• Cong Li,
• Gregory Moore,
• Umesh Muchhal,
• John Desjarlais,
• Matthew Bernett,
• Madeline Fort,
• Lingming Liang,
• Tao Osgood,
• Rodolfo Yabut,
• Sarav Kaliyaperumal,
• John Harrold,
• Jude Canon,
• Anna Rogojina,
• Raushan Kurmasheva,
• Peter Houghton,
• Olivier Nolan-Stevaux

Affiliations

Cong Li

1Amgen Inc., South San Francisco, CA, USA

Gregory Moore

Xencor, Inc., Monrovia, CA, USA

Umesh Muchhal

Aff390 Xencor, Inc. Monrovia CA USA

John Desjarlais

Aff390 Xencor, Inc. Monrovia CA USA

Matthew Bernett

Xencor, Inc., MONROVIA, CA, USA

Madeline Fort

1Amgen Inc., South San Francisco, CA, USA

Lingming Liang

1Amgen Inc., South San Francisco, CA, USA

Tao Osgood

1Amgen Inc., South San Francisco, CA, USA

Rodolfo Yabut

1Amgen Inc., South San Francisco, CA, USA

Sarav Kaliyaperumal

1Amgen Inc., South San Francisco, CA, USA

John Harrold

1Amgen Inc., South San Francisco, CA, USA

Jude Canon

1Amgen Inc., South San Francisco, CA, USA

Anna Rogojina

3University of Texas Health San Antonio, San Antonio, TX, USA

Raushan Kurmasheva

3University of Texas Health San Antonio, San Antonio, TX, USA

Peter Houghton

3University of Texas Health San Antonio, San Antonio, TX, USA

Olivier Nolan-Stevaux